Key Points
- Castle Biosciences insider Derek Maetzold sold 6,214 shares on May 7 for about $137,640, at an average price of $22.15 per share. The sale was made under a pre-arranged Rule 10b5-1 trading plan.
- The company reported quarterly EPS of -$0.49, matching analyst expectations, while revenue came in at $84.23 million, beating estimates of $79.23 million.
- Wall Street sentiment remains positive overall, with an average “Moderate Buy” rating and a consensus price target of $46.00, though the stock was trading well below that level at around $19.04.
Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Derek Maetzold sold 6,214 shares of the company's stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $22.15, for a total transaction of $137,640.10. Following the completion of the transaction, the insider owned 21,479 shares in the company, valued at approximately $475,759.85. This represents a 22.44% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Castle Biosciences Price Performance
Shares of CSTL opened at $19.04 on Tuesday. The company has a market capitalization of $577.48 million, a P/E ratio of -43.27 and a beta of 1.11. The company has a quick ratio of 6.53, a current ratio of 6.75 and a debt-to-equity ratio of 0.02. The firm has a 50 day moving average of $24.93 and a 200 day moving average of $32.09. Castle Biosciences, Inc. has a twelve month low of $14.59 and a twelve month high of $44.28.
Castle Biosciences (NASDAQ:CSTL - Get Free Report) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($0.49) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.49). Castle Biosciences had a negative return on equity of 2.77% and a negative net margin of 3.78%.The business had revenue of $84.23 million for the quarter, compared to analysts' expectations of $79.23 million. As a group, equities research analysts anticipate that Castle Biosciences, Inc. will post -1.4 earnings per share for the current fiscal year.
Institutional Trading of Castle Biosciences
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Federated Hermes Inc. purchased a new position in shares of Castle Biosciences during the 4th quarter valued at about $26,000. Farther Finance Advisors LLC grew its stake in shares of Castle Biosciences by 139,100.0% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,392 shares of the company's stock valued at $32,000 after acquiring an additional 1,391 shares during the period. State of Alaska Department of Revenue purchased a new stake in Castle Biosciences in the 3rd quarter worth approximately $35,000. Kemnay Advisory Services Inc. bought a new stake in Castle Biosciences during the 4th quarter worth approximately $35,000. Finally, CWM LLC raised its stake in Castle Biosciences by 80.6% during the 3rd quarter. CWM LLC now owns 1,911 shares of the company's stock worth $44,000 after acquiring an additional 853 shares during the period. Hedge funds and other institutional investors own 92.60% of the company's stock.
Wall Street Analysts Forecast Growth
Several equities research analysts recently commented on CSTL shares. Guggenheim increased their price objective on Castle Biosciences from $43.00 to $47.00 and gave the company a "buy" rating in a research report on Monday, January 26th. Lake Street Capital boosted their target price on Castle Biosciences from $35.00 to $52.00 and gave the stock a "buy" rating in a research report on Monday, January 12th. Canaccord Genuity Group lowered their target price on shares of Castle Biosciences from $50.00 to $40.00 and set a "buy" rating on the stock in a research note on Monday, April 20th. Robert W. Baird reduced their price target on shares of Castle Biosciences from $44.00 to $43.00 and set an "outperform" rating for the company in a research note on Thursday, May 7th. Finally, Morgan Stanley raised shares of Castle Biosciences to a "buy" rating in a report on Monday, March 2nd. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Castle Biosciences has an average rating of "Moderate Buy" and a consensus target price of $46.00.
Read Our Latest Stock Analysis on Castle Biosciences
About Castle Biosciences
(
Get Free Report)
Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company's proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.
The company's flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
